Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.

In an unbiased approach to biomarker discovery, we applied a highly multiplexed proteomic technology (SOMAscan, SomaLogic, Inc, Boulder, CO) to understand changes in proteins from paired serum samples at enrollment and after 8 weeks of TB treatment from 39 patients with pulmonary TB from Kampala, Ug...

Full description

Bibliographic Details
Main Authors: Mary A De Groote, Payam Nahid, Leah Jarlsberg, John L Johnson, Marc Weiner, Grace Muzanyi, Nebojsa Janjic, David G Sterling, Urs A Ochsner
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3630118?pdf=render
_version_ 1818524389498421248
author Mary A De Groote
Payam Nahid
Leah Jarlsberg
John L Johnson
Marc Weiner
Grace Muzanyi
Nebojsa Janjic
David G Sterling
Urs A Ochsner
author_facet Mary A De Groote
Payam Nahid
Leah Jarlsberg
John L Johnson
Marc Weiner
Grace Muzanyi
Nebojsa Janjic
David G Sterling
Urs A Ochsner
author_sort Mary A De Groote
collection DOAJ
description In an unbiased approach to biomarker discovery, we applied a highly multiplexed proteomic technology (SOMAscan, SomaLogic, Inc, Boulder, CO) to understand changes in proteins from paired serum samples at enrollment and after 8 weeks of TB treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in the Center for Disease Control and Prevention's Tuberculosis Trials Consortium (TBTC) Study 29. This work represents the first large-scale proteomic analysis employing modified DNA aptamers in a study of active tuberculosis (TB). We identified multiple proteins that exhibit significant expression differences during the intensive phase of TB therapy. There was enrichment for proteins in conserved networks of biological processes and function including antimicrobial defense, tissue healing and remodeling, acute phase response, pattern recognition, protease/anti-proteases, complement and coagulation cascade, apoptosis, immunity and inflammation pathways. Members of cytokine pathways such as interferon-gamma, while present, were not as highly represented as might have been predicted. The top proteins that changed between baseline and 8 weeks of therapy were TSP4, TIMP-2, SEPR, MRC-2, Antithrombin III, SAA, CRP, NPS-PLA2, LEAP-1, and LBP. The novel proteins elucidated in this work may provide new insights for understanding TB disease, its treatment and subsequent healing processes that occur in response to effective therapy.
first_indexed 2024-12-11T05:56:29Z
format Article
id doaj.art-8bef189a5f16488fada6ae29bf0d781b
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-11T05:56:29Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-8bef189a5f16488fada6ae29bf0d781b2022-12-22T01:18:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0184e6100210.1371/journal.pone.0061002Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.Mary A De GrootePayam NahidLeah JarlsbergJohn L JohnsonMarc WeinerGrace MuzanyiNebojsa JanjicDavid G SterlingUrs A OchsnerIn an unbiased approach to biomarker discovery, we applied a highly multiplexed proteomic technology (SOMAscan, SomaLogic, Inc, Boulder, CO) to understand changes in proteins from paired serum samples at enrollment and after 8 weeks of TB treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in the Center for Disease Control and Prevention's Tuberculosis Trials Consortium (TBTC) Study 29. This work represents the first large-scale proteomic analysis employing modified DNA aptamers in a study of active tuberculosis (TB). We identified multiple proteins that exhibit significant expression differences during the intensive phase of TB therapy. There was enrichment for proteins in conserved networks of biological processes and function including antimicrobial defense, tissue healing and remodeling, acute phase response, pattern recognition, protease/anti-proteases, complement and coagulation cascade, apoptosis, immunity and inflammation pathways. Members of cytokine pathways such as interferon-gamma, while present, were not as highly represented as might have been predicted. The top proteins that changed between baseline and 8 weeks of therapy were TSP4, TIMP-2, SEPR, MRC-2, Antithrombin III, SAA, CRP, NPS-PLA2, LEAP-1, and LBP. The novel proteins elucidated in this work may provide new insights for understanding TB disease, its treatment and subsequent healing processes that occur in response to effective therapy.http://europepmc.org/articles/PMC3630118?pdf=render
spellingShingle Mary A De Groote
Payam Nahid
Leah Jarlsberg
John L Johnson
Marc Weiner
Grace Muzanyi
Nebojsa Janjic
David G Sterling
Urs A Ochsner
Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.
PLoS ONE
title Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.
title_full Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.
title_fullStr Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.
title_full_unstemmed Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.
title_short Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.
title_sort elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment
url http://europepmc.org/articles/PMC3630118?pdf=render
work_keys_str_mv AT maryadegroote elucidatingnovelserumbiomarkersassociatedwithpulmonarytuberculosistreatment
AT payamnahid elucidatingnovelserumbiomarkersassociatedwithpulmonarytuberculosistreatment
AT leahjarlsberg elucidatingnovelserumbiomarkersassociatedwithpulmonarytuberculosistreatment
AT johnljohnson elucidatingnovelserumbiomarkersassociatedwithpulmonarytuberculosistreatment
AT marcweiner elucidatingnovelserumbiomarkersassociatedwithpulmonarytuberculosistreatment
AT gracemuzanyi elucidatingnovelserumbiomarkersassociatedwithpulmonarytuberculosistreatment
AT nebojsajanjic elucidatingnovelserumbiomarkersassociatedwithpulmonarytuberculosistreatment
AT davidgsterling elucidatingnovelserumbiomarkersassociatedwithpulmonarytuberculosistreatment
AT ursaochsner elucidatingnovelserumbiomarkersassociatedwithpulmonarytuberculosistreatment